Gathering the record
Relay is organizing the evidence and source boundaries.
Signal-biased dual GIP / GLP-1 receptor agonist
An experimental weight-loss drug, also called enicepatide. It is being tested for obesity and blood-sugar control.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Peer-reviewed Phase 1 evidence plus a randomized 469-participant Phase 2 obesity trial reported by the sponsor at 48 weeks.
The highest arm was reported at 22.5% placebo-adjusted loss under an efficacy estimand.
Short-term tolerability does not establish long-term or rare-event safety.
Enrollment and trial design are not evidence of benefit.
Clinical trial formulations do not validate research-market material.
Its receptor class is similar to other dual incretins, but it is a distinct molecule with its own evidence and safety record.
Risks & unknowns
Gastrointestinal adverse events were common and generally mild or moderate in the Phase 2 topline.
Other human evidenceSponsor summaries provide less detail than a full publication.
Open sourceGastrointestinal adverse events were common and generally mild or moderate in the Phase 2 topline.
Other human evidenceThe stated frequency is source-, product-, population-, route-, dose-, comparator-, and duration-specific; it is not a universal incidence estimate.
Open sourceRelay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational — Phase 2 obesity results; Phase 3 registered Independent full Phase 2 publication, Phase 3 durability and rare-event safety, cardiovascular outcomes, maintenance after discontinuation, and comparative performance.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
Adults with overweight or obesity received sponsor-controlled CT-388 in NCT04838405.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 4 weekly doses | 5–12 mg dose groups | Once weekly |
These are multiple-dose study levels. Separate single-dose groups received 0.5–7.5 mg. The range does not establish one starting dose or an escalation schedule.
CT-388 · Phase 1 randomized trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Peer-reviewed early research examined CT-388 in adults with overweight or obesity to characterize short-term safety, pharmacology, and initial metabolic signals.
Population: Adults with overweight or obesity
Design: Randomized first-in-human single- and multiple-ascending-dose study
Mechanisms
Enicepatide is a long-acting, signaling-biased dual agonist at GIPR and GLP-1R. A peer-reviewed first-in-human study established early pharmacology and short-term weight and glycemic signals. Roche subsequently reported a 469-participant, 48-week Phase 2 obesity trial with placebo-adjusted mean weight loss of 22.5% under an efficacy estimand at the highest 24 mg arm and 18.3% under the treatment-regimen estimand. Those figures are sponsor toplines rather than a complete peer-reviewed pivotal record. Gastrointestinal adverse events were common and mostly mild or moderate; discontinuation due to adverse events was higher than placebo. Registered Phase 3 Enith trials are designed to test longer-term efficacy and safety.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Phase 1, Phase 2, and registered Phase 3 research.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The largest result is a sponsor topline, not yet full peer-reviewed Phase 2 reporting.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was early phase and lasted no more than four weeks. It cannot establish durable weight outcomes, uncommon harms, an approved product standard, or equivalence to independently sourced material. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized first-in-human single- and multiple-ascending-dose study
Adults with overweight or obesity
Early cohorts showed dose-related weight reduction and target engagement.
Study administration: Once-weekly subcutaneous CT-388 or placebo
Limitations: Small early-phase cohorts and short exposure cannot establish durable efficacy or uncommon harms.
Randomized, double-blind, placebo-controlled pivotal trial
Adults with obesity or overweight
Enith-1 is intended to test the candidate in a larger, longer pivotal program.
Study administration: Once-weekly enicepatide or placebo
Limitations: No Phase 3 results were available at the evidence cutoff.
Randomized, double-blind, placebo-controlled dose-ranging trial
Adults with obesity
The sponsor reported placebo-adjusted mean weight loss up to 22.5% under an efficacy estimand and 18.3% under a treatment-regimen estimand.
Study administration: Once-weekly enicepatide dose groups or placebo
Limitations: Sponsor topline reporting is not equivalent to a complete peer-reviewed publication; estimands and attrition matter.
Official registry record for the completed obesity trial
Adults with obesity
The registry confirms the design and enrolled population behind the sponsor topline.
Study administration: Weekly subcutaneous CT-388 or placebo
Limitations: A registry record does not independently validate reported outcomes.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-01-27
2026-01-01 · NCT07351045
2025-12-01 · PMID 41319798 · NCT04838405
2024-07-29 · NCT06525935